Product Information
CYCLOSPORINE 0.05% EYE EMULSION is a generic product labeled by Devatis Inc., priced at $1.1803 per EA under NDC 73043000501. Its NADAC has been published 82 times since Mar 12, 2025.
FDA first approved this application on May 21, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/mL
Manufacturer
Devatis Inc.NDC
73043000501
Classification
Generic
Dosage Form
EMULSION
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
CYCLOSPORINEApproval Type
Generic (ANDA)
FDA Application
ANDA209811FDA Approved
5/21/2024
TE Code
AB
On Market Since
7/4/2024
Pharmacological Classes
Price Statistics
The NADAC for CYCLOSPORINE 0.05% EYE EMULSION has been published 82 times since Mar 12, 2025, and over the history we have for it it has declined 48.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.1803 per EA |
|---|---|
| All-time high | $2.5696 (Jun 11, 2025) |
| All-time low | $1.1803 (Sep 23, 2026) |
| 52-week high | $2.0995 |
| 52-week low | $1.1803 |
| Median price | $2.0236 |
| Average price | $1.9286 |
| Largest weekly change | -13.1% (Jun 17, 2026) |
| Weeks tracked | 82 |
| Tracking since | Mar 12, 2025 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 23% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Devatis Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cyclosporine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcineurin Inhibitor Immunosuppressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CYCLOSPORINE 0.05% EYE EMULSION?
The current National Average Drug Acquisition Cost (NADAC) for CYCLOSPORINE 0.05% EYE EMULSION, manufactured by Devatis Inc., is $1.1803 per EA (NDC 73043000501), effective Sep 30, 2026.
How has the price of CYCLOSPORINE 0.05% EYE EMULSION changed over time?
Over the history we have for it, the NADAC for CYCLOSPORINE 0.05% EYE EMULSION has declined 48.7%. It has been tracked across 82 weekly CMS publications since Mar 12, 2025.
What are the highest and lowest recorded NADAC prices for CYCLOSPORINE 0.05% EYE EMULSION?
Since Mar 12, 2025, the NADAC for CYCLOSPORINE 0.05% EYE EMULSION has ranged from a low of $1.1803 (Sep 23, 2026) to a high of $2.5696 (Jun 11, 2025), with a median of $2.0236 per EA.
Are there cheaper alternatives to CYCLOSPORINE 0.05% EYE EMULSION?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CYCLOSPORINE 0.05% EYE EMULSION, is $0.9094 per EA — about 23% below CYCLOSPORINE 0.05% EYE EMULSION.
Who manufactures CYCLOSPORINE 0.05% EYE EMULSION?
CYCLOSPORINE 0.05% EYE EMULSION (NDC 73043000501) is labeled by Devatis Inc., and CMS classifies it as a generic product.